 acut leukemia past experi futur perspect etoposid singl agent activ relaps refractori acut myelogen leukemia aml complet respons CR rate drug cytarabin azacytidin vinca alkaloid anthracyclin remiss rate patient aml experi etoposid acut lymphoblast leukemia extens drug activ combin cytarabin aclacinomycin addit etoposid cytarabin anthracyclin primari treatment aml respons rate compar standard regimen phase i/ii trial efficaci nove combin day etoposid day patient refractori aml result extend durat etoposid administr CR rate overal CR rate patient sequenti regimen idac idarubicin/cytarabin nove primari treatment adult patient aml cycl idac nove respons result pilot studi strategi patient CR further studi way efficaci strategi